最新ニュース TopBuild (NYSE:BLD) 株価情報

TOPBUILD CORP

TopBuild

TopBuild Corp is an installer and distributor of insulation products. Its operating segments involve the Installation and Specialty Distribution segment. The installation segment provides insulation installation services nationwide through contractor services business. Speciality Distribution segment distributes building and mechanical insulation, insulation accessories and other building product materials for the residential, commercial, and industrial end markets. The majority of revenue is earned from the installation segment. Its main customers are contractors. Other products include gutters, after-paint, garage doors, fireplaces, and fireproofing and stopping. TopBuild operates majorly in the United States.

TopBuild Corp

Blade Air Mobility, Inc. - Class A Common Stock

Blade Air Mobility Inc

Cambria Global Real Estate ETF

Ballard Power Systems, Inc. - Common Shares

Ballard Power Systems Inc

Builders FirstSource Inc

BLUE DIAMOND VENTURES INC by Blue Diamond Ventures, Inc.

Blue Diamond Ventures Inc

Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) has outperformed the market over the past 10 years by 2.2% on an annualized basis producing an average annual return of 12.94%. Currently, Home Depot has a market capitalization of $376.37 billion. 
Buying $100 In HD: If an investor had bought $100 of HD stock 10 years ago, it would be worth $337.04 today based on a price of $378.63 for HD at the time of writing.
<h3>Home Depot's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747349113_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$100 Invested In Home Depot 10 Years Ago Would Be Worth This Much Today

Sky Quarry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYQ#NASDAQ">SKYQ</a>) reported quarterly losses of $(0.16) per share. This is a 6.67 percent decrease over losses of $(0.15) per share from the same period last year. The company reported $6.33 million in sales this quarter. This is a 42.18 percent decrease over sales of $10.95 million the same period last year.

Earnings

SKYQ

Sky Quarry Q1 EPS $(0.16) Down From $(0.15) YoY, Sales $6.33M Down From $10.95M YoY

It&#8217;s been a roller coaster year for Wall Street as investors revise expectations during a period of <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020">rapidly changing policy announcements</a> in the White House. While markets turned bearish in March and April as the Trump Administration threatened tariffs on several U.S. trade partners, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) retraced some of its losses as the administration backed off some of its policy commitments and <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45376487/wall-street-edges-higher-as-inflation-cools-nasdaq-100-hits-10-week-highs">economic indicators look promising</a>.
Stephanie Link, chief investment officer and portfolio manager at Hightower Advisors, is optimistic about the market&#8217;s prospects if tariff concerns can be averted.
&#8220;I think the biggest surprise is that the Atlanta Fed [GDPNow] is at 2.3% in the face of everything,&#8221; Link wrote on Thursday. &#8220;Consumer continues to spend — Walmart is proof of that. Labor market remains solid and inflation is coming down albeit slowly. EPS up 12% is impressive as well. Get through tariffs and we'll start to focus on more positive things — lower taxes and deregulation.&#8221;
Link noted two contrarian plays she is bullish on as 2025 enters its second half. She called Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) her &#8220;favorite stock for 2025&#8221; amid the company&#8217;s turnaround under new leadership. While the Arlington, Virginia-based company&#8217;s shares have fallen from all-time highs due to regulatory woes and safety concerns, its stock is up over 20% in 2025.
Link also highlighted private equity giant KKR &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) as a firm benefiting from several positive trends.
&#8220;Added KKR this past week [with] the stock down 15% ytd and a play on growth, real assets, infrastructure and fee growth,&#8221; Link said.
She noted Quanta Services Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>), Eaton Corporation PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) and Rockwell Automation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) as other infrastructure plays.
Also Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45439079/powell-signals-fed-may-shift-its-inflation-strategy-after-5-year-economic-shake-up">Powell Signals Fed May Shift Inflation Strategy After 5 Years Of Economic Upheaval</a></li>
</ul>
Photo: Shutterstock

Equities

Hedge Funds

Exclusives

'My Favorite Stock For 2025,' Says Portfolio Manager, Who Also Notes Two Contrarian Plays During Growth Optimism

Femto Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMTO#NASDAQ">FMTO</a>) reported quarterly losses of $(2.50 thousand) per share. The company reported $141.20 thousand in sales this quarter.

FMTO

Femto Technologies Q1 EPS $(2.50K), Sales $141.20K

Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) reported quarterly losses of $(1.61) per share. This is a 56.49 percent increase over losses of $(3.70) per share from the same period last year.

KTTA

Pasithea Therapeutics Q1 EPS $(1.61) Up From $(3.70) YoY

Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) reported quarterly losses of $(1.40) per share. This is a 87.93 percent increase over losses of $(11.60) per share from the same period last year.

VINC

Vincerx Pharma Q1 EPS $(1.40) Up From $(11.60) YoY

HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(0.62) by 98.39 percent. This is a 211.82 percent decrease over earnings of $1.10 per share from the same period last year. The company reported quarterly sales of $2.00 million which missed the analyst consensus estimate of $3.38 million by 40.62 percent. This is a 94.52 percent decrease over sales of $36.60 million the same period last year.

Earnings Misses

HOOK

HOOKIPA Pharma Q1 EPS $(1.23) Misses $(0.62) Estimate, Sales $2.00M Miss $3.38M Estimate

Safety Shot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) reported quarterly losses of $(0.08) per share. This is a 75.76 percent increase over losses of $(0.33) per share from the same period last year. The company reported $42.10 thousand in sales this quarter. This is a 75.34 percent decrease over sales of $170.73 thousand the same period last year.

SHOT

Safety Shot Q1 EPS $(0.08) Up From $(0.33) YoY, Sales $42.10K Down From $170.73K YoY

Momentus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) reported quarterly losses of $(1.64) per share. This is a 82.25 percent increase over losses of $(9.24) per share from the same period last year. The company reported $322.00 thousand in sales this quarter. This is a 37.23 percent decrease over sales of $513.00 thousand the same period last year.

MNTS

Momentus Q1 EPS $(1.64) Up From $(9.24) YoY, Sales $322.00K Down From $513.00K YoY

Franklin Wireless (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FKWL#NASDAQ">FKWL</a>) reported quarterly losses of $(0.05) per share. This is a 50 percent increase over losses of $(0.10) per share from the same period last year. The company reported $8.01 million in sales this quarter. This is a 29.70 percent increase over sales of $6.18 million the same period last year.

FKWL

Franklin Wireless Q3 EPS $(0.05) Up From $(0.10) YoY, Sales $8.01M Up From $6.18M YoY

GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.64) by 48.44 percent. This is a 79.88 percent increase over losses of $(1.64) per share from the same period last year.

Earnings Beats

GTBP

GT Biopharma Q1 EPS $(0.33) Beats $(0.64) Estimate

HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) reported quarterly losses of $(0.05) per share. This is a 75 percent increase over losses of $(0.20) per share from the same period last year. The company reported $5.07 thousand in sales this quarter. This is a 99.55 percent decrease over sales of $1.13 million the same period last year.

HCWB

HCW Biologics Q1 EPS $(0.05) Up From $(0.20) YoY, Sales $5.07K Down From $1.13M YoY

Teva Pharmaceuticals (NYSE and TASE: TEVA)&nbsp;today announced that Moody's Investor Services ("Moody's") has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive.

Analyst Ratings

TEVA

Teva Pharmaceuticals Announced That Moody's Investor Services Has Raised The Company's Corporate Credit Rating To Ba1, Outlook Stable From Ba2, Outlook Positive

Jones Soda (OTC:<a class="ticker" href="https://www.benzinga.com/stock/JSDA#OTC">JSDA</a>) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $4.61 million in sales this quarter. This is a 7.82 percent decrease over sales of $5.00 million the same period last year.

JSDA

Jones Soda Q1 EPS $(0.01), Same YoY, Sales $4.61M Down From $5.00M YoY

Pioneer Power Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPSI#NASDAQ">PPSI</a>) affirms FY2025 sales outlook from $27.00 million-$29.00 million to $27.00 million-$29.00 million vs $27.79 million estimate.

Guidance

PPSI

Pioneer Power Solutions Affirms FY2025 Sales Guidance of $27.00M-$29.00M vs $27.79M Est

— Company Estimates Revenue Growth of 40%+ in Q1'25 —
— Company Reiterates Plans to Issue Final Q1'25 Results on May 20, 2025 —
Evolv Technologies Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>), a leading security technology company pioneering AI-based solutions designed to help create safer experiences, today provided an update on its preliminary financial results for the first quarter of 2025 as well as its upcoming plans to file its related Quarterly Report on Form 10-Q with the Securities and Exchange Commission.
Company Provides Preliminary Update for First Quarter of 2025
The Company today provided an update on preliminary results for the first quarter of 2025. Based on preliminary estimates which are subject to change, the Company expects total revenue to be between approximately $31.0 million and $32.0 million, compared to total revenue of $22.2 million in the first quarter of 2024. The Company expects less than $0.1 million of revenue to be related to the restatement previously completed by the Company. As previously disclosed, as of March 31, 2025, the Company had total cash, cash equivalents, and marketable securities of $35 million, with no outstanding debt. The Company will release final financial results for the first quarter of 2025 on Tuesday, May 20, 2025, after the market closes. Members of the Company's management team plan to host a live webcast at 4:30 p.m. Eastern Time on that day to discuss the financial results as well as management's outlook for the business. The conference call will be webcast live at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.evolvtechnology.com&amp;esheet=54255829&amp;newsitemid=20250515290964&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.evolvtechnology.com&amp;index=1&amp;md5=e090a672c321cba1771ef1925825cbe4">http://ir.evolvtechnology.com</a>.

EVLV

Evolv Technologies Estimates 40%+ Revenue Growth Between $31M - $32M In Q1 2025, Maintains $35M In Cash With No Debt, And Will Release Final Results On May 20, 2025

General

Foot Locker Faces A Potential $59.5M Termination Fee If It Ends The Merger Under Certain Conditions, Such As Changing Its Board Recommendation Or Signing A Superior Deal; Dick's Sporting Goods Risks Owing Foot Locker $95.5M If The Merger Is Terminated Due To Failure To Secure Required Antitrust Approvals

Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) reported quarterly losses of $(0.51) per share.

MOLN

CORRECTION: Molecular Partners Q1 EPS $(0.51)

XChange TEC. Inc. Receives Nasdaq Delisting Determination Letter

Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) reported quarterly losses of $(0.28) per share. This is a 173.68 percent decrease over earnings of $0.38 per share from the same period last year.

Comments

TopBuild

ニュース

最新ニュース TopBuild (NYSE:BLD) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル